Tagged with

Belgium Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives in Belgium, and the importance of multi-stakeholder collaboration to raise awareness and education around diabetes.   We have a long-term…

USA William H Lewis, chairman and CEO of serious and rare disease specialist Insmed, talks through the impact of recent product approvals in the US, preparations underway for international launches, the impact of COVID-19 on Insmed’s operations, and the firm’s highly promising clinical pipeline.   The most important element of any…

Europe In conversation with PharmaBoardroom Christoph Stoller and Adrian Van den Hoven of Medicines for Europe, the association representing the European generics, biosimilar and value-added-medicines industry, highlighted their members’ rapid response to the COVID-19 crisis and why Europe-wide reform is needed to avoid future medicine shortages and strengthen the supply chain.…

USA Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon.   Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled”…

USA John G. Singer examines why technological solutions are not a quick fix to overcoming the COVID-19 crisis and how a systems shift is crucial to securing better health outcomes in the long-term.   Strategic failure begins when you turn things over to technologists.   “My 18-year-old daughter, Caroline, responded quickly…

Global Speaking exclusively to PharmaBoardroom, Sanofi Genzyme Executive VP Bill Sibold outlines Sanofi’s strategy for its specialty care unit, the wealth of potential breakthrough assets in its pipeline, product launch strategies, and the post-COVID industry of tomorrow.   Since I joined in 2011, it feels as if my time with Sanofi…

Roche Swiss giant Roche tops Pharmaceutical Executive’s 2020 list of the world’s biggest pharma companies, up from second place in 2019 and third in 2018. Though its best-selling drugs are soon to face biosimilar competition, Roche’s diverse portfolio has ensured that it can continue to drive future sales growth. The firm…

Cell & Gene Therapy The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s quest for knowledge, costing USD three billion across 13 years. But even after nearly two decades, we have barely scratched…

Boehringer Ingelheim With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the Chinese biotech industry.   Boehringer Ingelheim has its sights set on establishing a deeper rapport with the Chinese biotech sector.…

Opinion In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular PharmaBoardroom contributor Yacine Sellam argues for the need for a more robust regulatory framework in Algeria and even the creation of a unified FDA-style regulator to counter this threat…

Belgium Serge Kemps, CEO of Nipro Medical Europe, sits down with PharmaBoardroom to shed light on Nipro’s unique corporate culture based on the Japanese concept of ‘sanpro yoshi’. Kemps also explains the importance of Belgium for Nipro, the innovation opportunities in the digitalisation of healthcare, and his strategic priorities since taking…

Medicines for Europe In the wake of the publication of Medicines for Europe’s Lessons Learned from COVID-19 policy paper, Christoph Stoller & Adrian van den Hoven outline the European generics, biosimilar and value-added-medicines industry’s rapid and comprehensive response to the COVID-19 crisis as well as the potential long-term shifts in European pharmaceutical policy…